BPC-157: Clinical Facts on the Tissue Repair Peptide
Medically reviewed by: Op. Dr. Ferhat İlen, ENT – Head & Neck Surgeon · Last updated:
BPC-157 is a 15-amino-acid synthetic peptide derived from a human gastric juice protein. Animal studies show favorable outcomes in tendon, muscle, and gastrointestinal tissue healing; however, robust controlled human trials are virtually absent.
Regulatory / evidence status: Not approved as a pharmaceutical drug in any country. Placed on the FDA category 2 list of bulk drug substances presenting significant safety concerns; prohibited by WADA.
What the Evidence Shows
Rodent studies demonstrate effects associated with angiogenesis, tendon healing, and preservation of the intestinal mucosal barrier.
In humans, only very small, uncontrolled pilot observations currently exist.
Safety and Risks
Long-term clinical safety is unknown. Due to its angiogenic mechanism, there is a theoretical oncologic risk in patients with active or previous malignancy.
Products marketed online as 'research chemicals' are frequently contaminated or incorrectly labeled.
The Fi Life Approach
For patients pursuing tissue repair, accurate diagnosis, physical therapy, nutritional optimization, and evidence-based medical modalities are prioritized. Research peptides are not prescribed or dispensed.
Frequently asked questions
Can athletes use BPC-157?
No; it is explicitly prohibited under the WADA Prohibited List.
Can BPC-157 be taken orally?
Oral forms have been evaluated in animal models; therapeutic efficacy in humans has not been established.
References
This page is for information only and does not replace diagnosis, treatment advice or a prescription. Peptide and drug assessments are made only after a physician consultation. No results are guaranteed.
Ask your physician whether it is right for you